NDA 021817 · Sandoz
Reclast
Zoledronic Acid · Intravenous
Priority reviewLast checked: Nov 19, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Apr 16, 2007
Approved uses
5
Original approval plus efficacy supplements
Registered trials
363
118 Phase 3, 24 recruiting
FAERS reports
40,714
35,240 serious, 5,181 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 3, 2026.
Reclast is a bisphosphonate indicated for: • Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) • Treatment to increase bone mass in men with osteoporosis ( 1.3 ) • Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) • Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) 1.1 Treatment of Osteoporosis in Postmenopausal Women Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Reclast reduces the incidence of fractures (hip, vertebral, and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Reclast reduces the incidence of new clinical fractures [see Clinical Studies ( 14.1 )]. 1.2 Prevention of Osteoporosis in Postmenopausal Women Reclast is indicated for prevention of osteoporosis in postmenopausal women [see Clinical Studies ( 14.2 )]. 1.3 Osteoporosis in Men Reclast is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies ( 14.3 )]. 1.4 Glucocorticoid-Induced Osteoporosis Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies ( 14.4 )]. 1.5 Paget's Disease of Bone Reclast is indicated for treatment of Paget's disease of bone...
Mechanism: Reclast is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover. The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The relatively long duration of action of zoledronic acid is attributable to its high binding affinity to bone mineral.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2009 Supplement 4 · Efficacy LetterLabel
- Mar 13, 2009 Supplement 3 · Efficacy LetterLabel
- Dec 19, 2008 Supplement 2 · Efficacy LetterLabel
- Jun 3, 2008 Supplement 1 · Efficacy LabelSummary ReviewLetter
- Apr 16, 2007 Original approval · Type 3 - New Dosage Form · priority review LetterReviewLabel
1 products under this application
- RECLAST · ZOLEDRONIC ACID EQ 5MG BASE/100ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Zoledronic Acid" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- HORIZON-PFT: Pivotal Fracture TrialPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00049829 · 7,700 participants · Start Jan 2002 · Primary completion Jun 2006
Drug: Zoledronic Acid · For: Osteoporosis
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Tucson, Arizona · 60 sites in all
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00127205 · 6,097 participants · Start Jul 2005 · Primary completion Dec 2017
Drug: clodronate disodium; ibandronate sodium and 1 more · For: Breast Cancer
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-TrialPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02181101 · 3,754 participants · Start Sep 2005 · Primary completion Sep 2013
Drug: FEC-DocGemzar adjuvant chemotherapy; FEC-Doc adjuvant chemotherapy and 2 more · For: Breast Neoplasms
Sites: Munich, Germany
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- Trial of Parkinson's And Zoledronic AcidPivotal-lookingCompleted
California Pacific Medical Center Research InstituteAcademic, hospital or other
NCT03924414 · 2,721 participants · Start Nov 15, 2019 · Primary completion Feb 28, 2026
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj · For: Parkinson Disease; Osteoporosis; Parkinsonism and 6 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 77 sites in all
- The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture PatientsPivotal-lookingStatus unknown
The University of Hong KongAcademic, hospital or other
NCT05743179 · 2,692 participants (planned) · Start Dec 5, 2022 · Primary completion May 2025
Drug: Zoledronate · For: Hip Fractures; Pneumonia
Sites: Hong Kong, Hong Kong; Kwun Tong, Hong Kong; Sham Shui Po, Hong Kong · 5 sites in all
- Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00145327 · 2,456 participants · Start May 2005 · Primary completion Nov 2009
Drug: Zoledronic Acid; Placebo · For: Osteoporosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Beverly Hills, California · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- arthralgia3,285
- pain3,218
- fatigue2,877
- nausea2,875
- pyrexia2,875
- osteonecrosis of jaw2,775
- death2,522
- headache2,431
- diarrhoea2,335
- vomiting2,090
- asthenia2,015
- myalgia1,908
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 92 |
| 2006 | 108 |
| 2007 | 281 |
| 2008 | 853 |
| 2009 | 1,339 |
| 2010 | 1,535 |
| 2011 | 2,241 |
| 2012 | 2,416 |
| 2013 | 996 |
| 2014 | 809 |
| 2015 | 1,331 |
| 2016 | 1,465 |
| 2017 | 1,673 |
| 2018 | 2,318 |
| 2019 | 2,676 |
| 2020 | 2,708 |
| 2021 | 2,705 |
| 2022 | 2,796 |
| 2023 | 3,043 |
| 2024 | 3,317 |
| 2025 | 3,556 |
| 2026 | 2,415 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Reclast (Zoledronic Acid/Mannitol-Water)
2024 spending
$106K
Beneficiaries
104
105 claims
Per beneficiary
$1,015
$10.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $71,172 |
| 2021 | $84,934 |
| 2022 | $55,662 |
| 2023 | $85,278 |
| 2024 | $105,537 |
Part B: Reclast* (Zoledronic Acid/Mannitol-Water*) · HCPCS J3489
2024 spending
$4.2M
Beneficiaries
96,550
143,810 claims
Per beneficiary
$43
2024 ASP limit $6.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,211,801 |
| 2021 | $6,038,889 |
| 2022 | $4,257,950 |
| 2023 | $5,306,181 |
| 2024 | $4,175,001 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, et al. · Lancet 2011 · Clinical Trial, Phase III, Comparative Study
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J, Lin X, Sun L, et al. · J Clin Endocrinol Metab 2024 · Randomized Controlled Trial, Comparative Study
- Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. · N Engl J Med 2007 · Multicenter Study, Randomized Controlled Trial
- Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T, Morimoto T, Ito K, et al. · Osteoporos Int 2024 · Meta-Analysis, Comparative Study
- Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT, Lipton A, Body JJ, et al. · J Clin Oncol 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials.
He B, Zhao JQ, Zhang MZ, et al. · Eur Rev Med Pharmacol Sci 2021 · Meta-Analysis, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.